ES2949335T3 - Procedimiento y compuestos para la inhibición del complejo MCM y su aplicación en el tratamiento de cáncer - Google Patents

Procedimiento y compuestos para la inhibición del complejo MCM y su aplicación en el tratamiento de cáncer Download PDF

Info

Publication number
ES2949335T3
ES2949335T3 ES13787939T ES13787939T ES2949335T3 ES 2949335 T3 ES2949335 T3 ES 2949335T3 ES 13787939 T ES13787939 T ES 13787939T ES 13787939 T ES13787939 T ES 13787939T ES 2949335 T3 ES2949335 T3 ES 2949335T3
Authority
ES
Spain
Prior art keywords
cells
mcm
deacetyltanginine
desacetyltanginine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13787939T
Other languages
English (en)
Spanish (es)
Inventor
Chun Liang
Zhihong Jiang
Ziyi Wang
Zhiling Yu
Jingrong Wang
Liping Bai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hong Kong University of Science and Technology
Hong Kong Baptist University HKBU
Macau University of Science and Technology
Original Assignee
Hong Kong University of Science and Technology
Hong Kong Baptist University HKBU
Macau University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Kong University of Science and Technology, Hong Kong Baptist University HKBU, Macau University of Science and Technology filed Critical Hong Kong University of Science and Technology
Application granted granted Critical
Publication of ES2949335T3 publication Critical patent/ES2949335T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES13787939T 2012-05-09 2013-05-09 Procedimiento y compuestos para la inhibición del complejo MCM y su aplicación en el tratamiento de cáncer Active ES2949335T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644442P 2012-05-09 2012-05-09
PCT/US2013/040287 WO2013169989A1 (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Publications (1)

Publication Number Publication Date
ES2949335T3 true ES2949335T3 (es) 2023-09-27

Family

ID=49551267

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13787939T Active ES2949335T3 (es) 2012-05-09 2013-05-09 Procedimiento y compuestos para la inhibición del complejo MCM y su aplicación en el tratamiento de cáncer

Country Status (9)

Country Link
US (1) US11648258B2 (enExample)
EP (2) EP4248978A3 (enExample)
JP (6) JP2015517500A (enExample)
CN (2) CN110412285B (enExample)
AU (1) AU2013259486B2 (enExample)
CA (2) CA3111702C (enExample)
ES (1) ES2949335T3 (enExample)
IN (1) IN2014MN02513A (enExample)
WO (1) WO2013169989A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019283946B2 (en) * 2017-05-19 2021-05-20 Enkang Pharmaceuticals (Guangzhou), Ltd. Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms
CN108948119B (zh) 2017-05-19 2023-11-21 恩康药业科技（广州）有限公司 黄夹次甙乙多晶型的晶型特征、制备方法及在抗癌上的应用
CN114177189A (zh) * 2019-03-27 2022-03-15 天津中医药大学 黄夹次乙苷作为抗肿瘤药物的应用
WO2025077888A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 一种适合外用的化合物及药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0592990A (ja) 1991-08-06 1993-04-16 Taisho Pharmaceut Co Ltd カルデノライド誘導体
WO2002014343A1 (en) 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
US8318922B2 (en) 2002-08-29 2012-11-27 The Hong Kong Polytechnic University Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins
US7393950B2 (en) 2002-08-29 2008-07-01 Hong Kong University Of Science & Technology Antisense oligonucleotides targeted to human CDC45
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
DE10248751A1 (de) 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
US20070207120A1 (en) * 2004-04-14 2007-09-06 Sarah Drayton Selective Killing Of Cancer Cells By Induction Of Acetyltransferase Via Tnf-Alpha And Il-6
US20090022708A1 (en) 2004-12-22 2009-01-22 Lobie Peter E Trefoil Factors and Methods of Treating Proliferation Disorders Using Same
EP1787645A1 (en) 2005-11-18 2007-05-23 Institut Curie New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway
US20090018088A1 (en) * 2006-10-27 2009-01-15 University Of Louisville Research Foundation Treating cancer with cardiac glycosides
CN101683359B (zh) * 2008-09-28 2012-05-09 上海秀新臣邦医药科技有限公司 一种治疗肿瘤的中药组合物及其制备方法
CN101726577A (zh) * 2008-10-13 2010-06-09 中山大学 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法
WO2010068247A1 (en) 2008-12-10 2010-06-17 Sloan-Kettering Institute For Cancer Research Cardenolides for the treatment of ocular cancer
CN102219821A (zh) 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
AU2013259486A1 (en) 2014-12-18
EP4248978A2 (en) 2023-09-27
CA3111702C (en) 2025-03-18
EP2846807A4 (en) 2016-07-27
CA3111702A1 (en) 2013-11-14
EP2846807B1 (en) 2023-06-07
CA2873283C (en) 2021-05-04
US20150099712A1 (en) 2015-04-09
WO2013169989A1 (en) 2013-11-14
AU2013259486B2 (en) 2019-12-12
JP2021193132A (ja) 2021-12-23
JP2025169320A (ja) 2025-11-12
EP2846807A1 (en) 2015-03-18
EP4248978A3 (en) 2023-11-08
CN104736157A (zh) 2015-06-24
JP2020073544A (ja) 2020-05-14
JP2018100274A (ja) 2018-06-28
IN2014MN02513A (enExample) 2015-07-17
JP2024001049A (ja) 2024-01-09
EP2846807C0 (en) 2023-06-07
JP2015517500A (ja) 2015-06-22
CN104736157B (zh) 2019-06-11
US11648258B2 (en) 2023-05-16
CN110412285A (zh) 2019-11-05
CA2873283A1 (en) 2013-11-14
CN110412285B (zh) 2022-11-15

Similar Documents

Publication Publication Date Title
Kumar et al. Usnic acid induces apoptosis in human gastric cancer cells through ROS generation and DNA damage and causes up-regulation of DNA-PKcs and γ-H2A. X phosphorylation
Song et al. Galangin potentiates human breast cancer to apoptosis induced by TRAIL through activating AMPK
JP2024001049A (ja) Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
Ma et al. Downregulation of TIGAR sensitizes the antitumor effect of physapubenolide through increasing intracellular ROS levels to trigger apoptosis and autophagosome formation in human breast carcinoma cells
Han et al. Sweroside eradicated leukemia cells and attenuated pathogenic processes in mice by inducing apoptosis
Yang et al. Oridonin triggers apoptosis in colorectal carcinoma cells and suppression of microRNA-32 expression augments oridonin-mediated apoptotic effects
Pandey et al. Prooxidative activity of plumbagin induces apoptosis in human pancreatic ductal adenocarcinoma cells via intrinsic apoptotic pathway
Guan et al. Breviscapine (BVP) inhibits prostate cancer progression through damaging DNA by minichromosome maintenance protein-7 (MCM-7) modulation
Li et al. The effect of dihydroartemisinin on the malignancy and epithelial-mesenchymal transition of gastric cancer cells
JP2024069632A (ja) 生物活性Ｇａｎｏｄｅｒｍａ ｌｕｃｉｄｕｍ化合物および抗がん誘導体の合成；細胞の局在のためのエルゴステロールペルオキシドプローブ
Abusaliya et al. Investigation of prunetrin induced G2/M cell cycle arrest and apoptosis via Akt/mTOR/MAPK pathways in hepatocellular carcinoma cells
Zhang et al. SCP-7, a germacrane-type sesquiterpene lactone derivative, induces ROS-mediated apoptosis in NSCLC cells in vitro and in vivo
Rudolf et al. Antiproliferative effects of α-tomatine are associated with different cell death modalities in human colon cancer cells
Liu et al. Modification of a natural diterpene and its antitumor mechanism: Promoting apoptosis, suppressing migration, and inhibiting angiogenesis
ES2250406T3 (es) Derivados de triterpenoides.
KR102293156B1 (ko) 간세포 암종에 대한 치료제로서의 우트트로시드(Uttroside) B 및 이의 유도체
Goswami et al. Antiproliferative potential of a novel parthenin analog P16 as evident by apoptosis accompanied by down-regulation of PI3K/AKT and ERK pathways in human acute lymphoblastic leukemia MOLT-4 cells
US20230293564A1 (en) Method and compounds for inhibiting the MCM complex and their application in cancer treatment
Zhao et al. 4, 5-Diphenyl-2-methyl picolinate induces cellular senescence by accumulating DNA damage and activating associated signaling pathways in gastric cancer
HK40100635A (en) Method and compounds for inhibiting the mcm complex and their application in cancer treatment
HK40016841B (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
HK40016841A (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
Niu et al. Scutebarbatine B Exerts Anti‐Breast Cancer Activity by Inducing Cell Cycle Arrest and Apoptosis Through Multiple Pathways
Zhang et al. Protopine Triggers Apoptosis Via The Intrinsic Pathway and Regulation of ROS/PI3K/Akt Signalling Pathway in Liver Carcinoma
JP6931889B2 (ja) 白血病幹細胞のニッチ形成抑制活性を有する海洋生物由来の抽出物、化合物及び医薬組成物